ONC

SEC source: 0001651308-20-000103 · wf-form4_159545083259861.xml · nonDerivative · entry 6

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,700

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2019.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.04 to $250.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000103 · wf-form4_159545083259861.xml · nonDerivative · entry 5

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,700

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2019.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.99 to $249.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000102 · wf-form4_159536460705456.xml · nonDerivative · entry 5

Wu Xiaobin · CIK 0001739452 · President & GM China

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.00 to $250.12, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000102 · wf-form4_159536460705456.xml · nonDerivative · entry 4

Wu Xiaobin · CIK 0001739452 · President & GM China

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2019.

SEC source: 0001651308-20-000098 · wf-form4_159484765431414.xml · nonDerivative · entry 8

Wu Xiaobin · CIK 0001739452 · President & GM China

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2019.

SEC source: 0001651308-20-000098 · wf-form4_159484765431414.xml · nonDerivative · entry 7

Wu Xiaobin · CIK 0001739452 · President & GM China

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2019.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.75 to $244.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000098 · wf-form4_159484765431414.xml · nonDerivative · entry 6

Wu Xiaobin · CIK 0001739452 · President & GM China

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.43 to $243.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000098 · wf-form4_159484765431414.xml · nonDerivative · entry 5

Wu Xiaobin · CIK 0001739452 · President & GM China

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.00 to $240.56, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001638599-20-000663 · doc4_6790.xml · nonDerivative · entry 8

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 18,840,379

F8 · price: On July 15, 2020, 667 and Life Sciences purchased 994,276 and 13,589,904 Ordinary Shares, respectively in a registered direct offering by the Issuer at a price of $14.2308 per Ordinary Share.

F3 · ownership.nature: Ordinary Shares are convertible into ADS on a 13:1 basis.

F5 · ownership.nature: As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Baker Brothers Life Sciences, L.P, ("Life Sciences", and together with 667, the "Funds"), Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in ADS, as applicable, reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F6 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: On July 15, 2020, 667 and Life Sciences purchased 994,276 and 13,589,904 Ordinary Shares, respectively in a registered direct offering by the Issuer at a price of $14.2308 per Ordinary Share.

F9 · ownership.nature: Includes beneficial ownership of 9,282 Ordinary Shares received from vested restricted share units convertible solely into Ordinary Shares of the Issuer ("RSU's") each previously granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser in their capacity as directors of the Issuer. Michael Goller and Ranjeev Krishana serve on the board of directors of the Issuer (the "Board") as representatives of the Funds. Reflects the vesting of 9,282 RSU's which were inadvertently reported as 9,290 RSU's for each of Michael Goller and Ranjeev Krishana in previous Forms 4.

F10 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSU's and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSU's, Share Options, and Ordinary Shares received upon the exercise of Share Options (i.e. no direct pecuniary interest).

F13 · ownership.nature: Pursuant to agreements between Michael Goller and Ranjeev Krishana and the Adviser, the Adviser has voting and dispositive power over the Share Options, Ordinary Shares received upon vesting of RSU's and any Ordinary Shares received as a result of the exercise of Share Options.

F15 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F17 · ownership.nature: 18,821,790 Ordinary Shares held by Life Sciences were converted into 1,447,830 ADS without consideration and without a change in pecuniary interest.

SEC source: 0001638599-20-000663 · doc4_6790.xml · nonDerivative · entry 7

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,021,851

F8 · price: On July 15, 2020, 667 and Life Sciences purchased 994,276 and 13,589,904 Ordinary Shares, respectively in a registered direct offering by the Issuer at a price of $14.2308 per Ordinary Share.

F3 · ownership.nature: Ordinary Shares are convertible into ADS on a 13:1 basis.

F4 · ownership.nature: As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in ADS, reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F6 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: On July 15, 2020, 667 and Life Sciences purchased 994,276 and 13,589,904 Ordinary Shares, respectively in a registered direct offering by the Issuer at a price of $14.2308 per Ordinary Share.

F9 · ownership.nature: Includes beneficial ownership of 9,282 Ordinary Shares received from vested restricted share units convertible solely into Ordinary Shares of the Issuer ("RSU's") each previously granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser in their capacity as directors of the Issuer. Michael Goller and Ranjeev Krishana serve on the board of directors of the Issuer (the "Board") as representatives of the Funds. Reflects the vesting of 9,282 RSU's which were inadvertently reported as 9,290 RSU's for each of Michael Goller and Ranjeev Krishana in previous Forms 4.

F10 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSU's and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSU's, Share Options, and Ordinary Shares received upon the exercise of Share Options (i.e. no direct pecuniary interest).

F13 · ownership.nature: Pursuant to agreements between Michael Goller and Ranjeev Krishana and the Adviser, the Adviser has voting and dispositive power over the Share Options, Ordinary Shares received upon vesting of RSU's and any Ordinary Shares received as a result of the exercise of Share Options.

F14 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F16 · ownership.nature: 994,266 Ordinary Shares held by 667 were converted into 76,482 ADS without consideration and without a change in pecuniary interest.

SEC source: 0000899243-20-019383 · doc4.xml · nonDerivative · entry 1

AMGEN INC · CIK 0000318154 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,249,845

F1 · balance_after: Includes 206,635,013 securities represented by American Depositary Shares, each of which represents 13 Ordinary Shares of the Issuer.

SEC source: 0001651308-20-000098 · wf-form4_159484765431414.xml · nonDerivative · entry 4

Wu Xiaobin · CIK 0001739452 · President & GM China

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2019.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 20

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F21 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.47 to $204.28, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 19

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,854

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.00 to $202.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 18

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,688

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.00 to $201.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 17

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,529

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.00 to $200.96, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 16

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,429

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.81 to $199.80, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 15

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,229

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.65 to $198.22, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 14

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,929

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.41 to $196.72, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 13

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.44 to $200.30, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 12

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,318

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.43 to $199.42, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 11

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,792

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.43 to $198.41, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 10

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,293

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.27 to $197.24, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000094 · wf-form4_159432737534442.xml · derivative · entry 4

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,180

Underlying: Ordinary Shares · 50,973 shares

Expires 2028-06-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F4 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 26, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.

SEC source: 0001651308-20-000094 · wf-form4_159432737534442.xml · nonDerivative · entry 3

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

SEC source: 0001651308-20-000094 · wf-form4_159432737534442.xml · nonDerivative · entry 2

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,921

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001651308-20-000095 · wf-form4_159432751777592.xml · nonDerivative · entry 5

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2019.

F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 9

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.10 to $198.59, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 8

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,561

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.03 to $198.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 7

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,861

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.03 to $197.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 6

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,562

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.02 to $195.73, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000089 · wf-form4_159363616189353.xml · nonDerivative · entry 10

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F9 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2017, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.00 to $192.255, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000089 · wf-form4_159363616189353.xml · nonDerivative · entry 9

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,800

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F9 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2017, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.00 to $191.41, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000092 · wf-form4_159406872145556.xml · nonDerivative · entry 8

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2018 to fulfill a tax payment obligation in connection with the vesting of restricted share unit awards previously granted to the Reporting Person.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.09 to $192.54, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000092 · wf-form4_159406872145556.xml · nonDerivative · entry 7

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 457

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2018 to fulfill a tax payment obligation in connection with the vesting of restricted share unit awards previously granted to the Reporting Person.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.05 to $191.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000092 · wf-form4_159406872145556.xml · nonDerivative · entry 6

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,057

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2018 to fulfill a tax payment obligation in connection with the vesting of restricted share unit awards previously granted to the Reporting Person.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.86 to $190.85, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000092 · wf-form4_159406872145556.xml · nonDerivative · entry 5

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,157

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2018 to fulfill a tax payment obligation in connection with the vesting of restricted share unit awards previously granted to the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.69 to $189.53, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · derivative · entry 14

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 461,075

Underlying: Ordinary Shares · 19,500 shares

Expires 2026-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F12 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.

SEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · nonDerivative · entry 12

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

SEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · nonDerivative · entry 11

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.24 to $193.20, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · nonDerivative · entry 10

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 298

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.13 to $191.87, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · nonDerivative · entry 9

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 798

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.77 to $189.09, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · nonDerivative · entry 8

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,200

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.40 to $188.27, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · nonDerivative · entry 7

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · nonDerivative · entry 6

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019 to cover tax withholdings in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.

SEC source: 0001651308-20-000089 · wf-form4_159363616189353.xml · nonDerivative · entry 8

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

SEC source: 0001651308-20-000089 · wf-form4_159363616189353.xml · nonDerivative · entry 7

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.50 to $193.47, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000089 · wf-form4_159363616189353.xml · nonDerivative · entry 6

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,135

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.34 to $192.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price.

SEC source: 0001651308-20-000088 · wf-form4_159363579383420.xml · nonDerivative · entry 2

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a sale event.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.00 to $191.34, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · derivative · entry 13

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 283,153

Underlying: Ordinary Shares · 27,027 shares

Expires 2028-06-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F11 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 26, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.